Asian Journal of Pediatric Research

Severe childhood epilepsy syndromes, encompassing the developmental and epileptic encephalopathies together with related drug-resistant electroclinical constellations, remain among the most challenging conditions in paediatric neurology. They combine frequent, treatment-resistant seizures with developmental impairment, substantial comorbidity, and elevated premature mortality. The past two decades have transformed the field: a revised syndrome classification, an expanding catalogue of monogenic causes, and a succession of syndrome-specific and mechanism-based therapies have altered both diagnosis and management. This critical narrative review synthesises evidence on the clinical features, aetiologies, and therapeutic options for these syndromes, and evaluates the strength, consistency, and limitations of that evidence rather than cataloguing individual studies. Literature was selected from bibliographic searching, citation chaining, and appraisal of consensus statements and clinical guidelines, with every cited reference and its digital object identifier independently verified. Several themes emerge. Aetiological diagnosis, particularly through broad genetic testing, now carries direct management consequences, yet a diagnostic gap persists and genotype does not map cleanly onto phenotype or treatment response. Syndrome-specific pharmacotherapy is supported by robust randomised evidence for a small number of agents in Dravet syndrome, Lennox-Gastaut syndrome, and CDKL5 deficiency disorder, but head-to-head comparisons, long-term developmental outcomes, and effects on the encephalopathy itself remain poorly characterised. Mechanism-based and disease-modifying strategies, including mammalian target of rapamycin inhibition, pre-emptive treatment, and antisense oligonucleotides, represent a conceptual shift from seizure suppression toward disease modification, though the durability and developmental impact of these approaches are not yet established. Sudden unexpected death in epilepsy and other causes of early mortality remain insufficiently mitigated. The available evidence supports cautious optimism: outcomes are improving, but confidence in many conclusions is constrained by small samples, heterogeneous endpoints, short follow-up, and reliance on seizure count as the dominant outcome. Priorities include earlier aetiological diagnosis, developmentally meaningful outcome measures, and trials designed to test disease modification rather than seizure frequency alone.